Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP)
inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration
of the effects of stroke, head trauma, and neurodegenerative disease.
##STR1##
As cancer therapeutics, the compounds of the invention may be used, e.g., in combination
with cytotoxic agents and/or radiation.